Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.

NCT04493853 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04493853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04493853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 13, 2020
Completion date
March 31, 2027
Enrollment
1,012 (actual)
Sites
323

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-sensitive prostate cancer